23rd Dec 2019 13:37
(Alliance News) - Sensyne Health PLC on Monday said it has signed a research project with Swiss pharmaceutical giant Roche Holdings AG.
No financial terms were disclosed.
The AIM-listed clinical artificial intelligence technology company explained that the collaboration will focus on identifying patient populations in one disease area and assessing and collating anonymised patient data with anonymised electronic patient record information to support clinical trial planning.
"This is an important collaboration and marks Sensyne's increasing activity in partnering with leading pharmaceutical companies using our clinical AI platform. It is particularly pleasing given Roche's progressive approach to data and technology-driven personalised healthcare," said Chief Executive Paul Drayson.
Sensyne Health shares were trading 1.6% higher in London on Monday at 71.10 pence each.
By Evelina Grecenko; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
SENS.L